Structure-Activity Relationship Studies and Optimization of 4-Hydroxypyridones as GPR84 Agonists
GPR84 is a putative medium-chain fatty acid receptor that is implicated in regulation of inflammation and fibrogenesis. Studies have indicated that GPR84 agonists may have therapeutic potential in diseases such as Alzheimer's disease, atherosclerosis, and cancer, but there is a lack of quality tool compounds to explore this potential. The fatty acid analogue LY237 (4a) is the most potent GPR84 agonist disclosed to date but has unfavorable physicochemical properties. We here present a SAR study of 4a. Several highly potent agonists were identified with EC50 down to 28 pM, and with SAR generally in excellent agreement with structure-based modeling. Proper incorporation of rings and polar groups resulted in the identification of TUG-2099 (4s) and TUG-2208 (42a), both highly potent GPR84 agonists with lowered lipophilicity and good to excellent solubility, in vitro permeability, and microsomal stability, which will be valuable tools for exploring the pharmacology and therapeutic prospects of GPR84.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Journal of medicinal chemistry - 67(2024), 5 vom: 14. März, Seite 3542-3570 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ieremias, Loukas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fatty Acids |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.jmedchem.3c01923 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368716724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368716724 | ||
| 003 | DE-627 | ||
| 005 | 20240315233351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jmedchem.3c01923 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM368716724 | ||
| 035 | |a (NLM)38381650 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ieremias, Loukas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure-Activity Relationship Studies and Optimization of 4-Hydroxypyridones as GPR84 Agonists |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a GPR84 is a putative medium-chain fatty acid receptor that is implicated in regulation of inflammation and fibrogenesis. Studies have indicated that GPR84 agonists may have therapeutic potential in diseases such as Alzheimer's disease, atherosclerosis, and cancer, but there is a lack of quality tool compounds to explore this potential. The fatty acid analogue LY237 (4a) is the most potent GPR84 agonist disclosed to date but has unfavorable physicochemical properties. We here present a SAR study of 4a. Several highly potent agonists were identified with EC50 down to 28 pM, and with SAR generally in excellent agreement with structure-based modeling. Proper incorporation of rings and polar groups resulted in the identification of TUG-2099 (4s) and TUG-2208 (42a), both highly potent GPR84 agonists with lowered lipophilicity and good to excellent solubility, in vitro permeability, and microsomal stability, which will be valuable tools for exploring the pharmacology and therapeutic prospects of GPR84 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Receptors, G-Protein-Coupled |2 NLM | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 650 | 7 | |a GPR84 protein, human |2 NLM | |
| 700 | 1 | |a Kaspersen, Mads H |e verfasserin |4 aut | |
| 700 | 1 | |a Manandhar, Asmita |e verfasserin |4 aut | |
| 700 | 1 | |a Schultz-Knudsen, Katrine |e verfasserin |4 aut | |
| 700 | 1 | |a Vrettou, Christina Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Pokhrel, Rina |e verfasserin |4 aut | |
| 700 | 1 | |a Heidtmann, Christoffer V |e verfasserin |4 aut | |
| 700 | 1 | |a Jenkins, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Kanellou, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Marsango, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yueming |e verfasserin |4 aut | |
| 700 | 1 | |a Bräuner-Osborne, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Rexen Ulven, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Milligan, Graeme |e verfasserin |4 aut | |
| 700 | 1 | |a Ulven, Trond |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 67(2024), 5 vom: 14. März, Seite 3542-3570 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:5 |g day:14 |g month:03 |g pages:3542-3570 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.3c01923 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 5 |b 14 |c 03 |h 3542-3570 | ||